IceCure MedicalICCM
ICCM
About: Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Employees: 66
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
8% more funds holding
Funds holding: 13 [Q4 2024] → 14 (+1) [Q1 2025]
0.05% less ownership
Funds ownership: 0.28% [Q4 2024] → 0.23% (-0.05%) [Q1 2025]
9% less capital invested
Capital invested by funds: $169K [Q4 2024] → $154K (-$14.9K) [Q1 2025]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$2.50
157%
upside
Avg. target
$2.50
157%
upside
High target
$2.50
157%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen | 157%upside $2.50 | Buy Reiterated | 29 May 2025 |
Financial journalist opinion
Based on 4 articles about ICCM published over the past 30 days
Neutral
PRNewsWire
1 week ago
IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes
IceCure has 20+ patents in the U.S. and the Company anticipates further market traction upon FDA's marketing authorization decision in early-stage breast cancer CAESAREA, Israel , June 9, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application titled 'Cryogen Flow Control'.
Neutral
Seeking Alpha
2 weeks ago
IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript
IceCure Medical Ltd (NASDAQ:ICCM ) Q1 2025 Earnings Conference Call May 28, 2025 10:00 AM ET Company Participants Michael Polyviou - IR Eyal Shamir - CEO Ronen Tsimerman - CFO and COO Conference Call Participants Anthony Vendetti - Maxim Group Kemp Dolliver - Brookline Capital Markets Operator Good morning, and thank you for standing by. Currently, all the participants are in a listen-only mode.
Neutral
PRNewsWire
2 weeks ago
IceCure Medical Reports First Quarter 2025 Financial Results
Recently finalized and delivered proposed post market study plan to the FDA; Awaiting marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer Continues to see rising interest in North America for ProSense® Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel , May 28, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the three months ended March 31, 2025.
Neutral
PRNewsWire
3 weeks ago
IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025
CAESAREA, Israel , May 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2025 before the Nasdaq Stock Market opens on Wednesday, May 28, 2025.
Neutral
PRNewsWire
1 month ago
IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation
Breast surgeons expressed strong interest in participating in IceCure's planned post-market study for ProSense® in the treatment of early-stage breast cancer ICE3 study named as one of the "Best Papers of 2024" Cryoablation was mentioned favorably during the ASBrS Presidential Address CAESAREA, Israel , May 6, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it participated in the American Society of Breast Surgeons (ASBrS) 2025 Annual Meeting on April 30 – May 4, 2025 in Las Vegas.
Neutral
PRNewsWire
1 month ago
IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer
Final marketing authorization decision for early-stage breast cancer is expected upon the FDA's approval of IceCure's post-market study plan IceCure to engage with potential clinical sites, breast surgeons and radiologists for the post-market study including at the upcoming American Society of Breast Surgeons (ASBrS) Annual Meeting ProSense® would become the first-in-class minimally invasive choice—a major advancement in women's health and a new paradigm in breast cancer care as a simple out-patient procedure U.S. sales and distribution team ready to drive sales of ProSense® systems and disposable probes—supporting medical community and patients looking for a new minimally invasive option to lumpectomy CAESAREA, Israel , April 30, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it concluded a productive meeting with the leadership of the U.S. Food and Drug Administration's ("FDA") Center for Devices and Radiological Health ("CDRH") regarding the Company's De Novo marketing authorization request for ProSense® in the treatment of early-stage low risk breast cancer when combined with adjuvant endocrine therapy for women aged 70 and over which represents approximately 46,000 patients annually in the U.S. During the meeting, the FDA requested that IceCure conduct a study after marketing authorization has been granted ("the post-market study"), with the aim of producing additional data in this indication.
Neutral
PRNewsWire
1 month ago
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium
Two sold-out SBI breast cryoablation courses featured hands-on training with ProSense® IceCure hosted a VIP Exhibitor Hour featuring Dr. Robert C. Ward, a specialist in women's imaging and breast cryoablation CAESAREA, Israel , April 28, 2025 /PRNewswire/ -- IceCure Medical Ltd.
Neutral
PRNewsWire
1 month ago
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation
Breast cancer cryoablation was a major focus at ECIO 2025 with a dedicated scientific session Independent studies of ProSense® featured in scientific sessions and abstracts including data from the THERMAC trial stating 95% of patients said they would choose thermal ablation over breast conserving surgery In-booth expert exchange session on breast cancer cryoablation from the perspective of both breast surgeons and interventional oncologists by Sophie Wooldrik, MD & Prof. Tomas Vogl, MD respectively Three hands-on device trainings, including ProSense® CAESAREA, Israel , April 22, 2025 /PRNewswire/ -- IceCure Medical Ltd.
Positive
Zacks Investment Research
2 months ago
IceCure Medical Stock Dips Despite Positive ICESECRET Study Results
ICCM reports strong kidney cancer cryoablation study results, showcasing 88.7% recurrence-free rates and reinforcing its position in cryoablation technology.
Neutral
Seeking Alpha
2 months ago
IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript
IceCure Medical Ltd (NASDAQ:ICCM ) Q4 2024 Earnings Conference Call March 27, 2025 10:00 AM ET Company Participants Michael Polyviou - Investor Relations Eyal Shamir - Chief Executive Officer and Director Ronen Tsimerman - Chief Financial Officer and Chief Operating Officer Conference Call Participants Kemp Dolliver - Brookline Capital Markets Anthony Vendetti - Maxim Group Operator Good morning, and thank you for standing by. Currently, all the participants' are in a listen-only mode.
Charts implemented using Lightweight Charts™